NEW SHARP PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (“NEW SHARP PHARMACEUTICALS”) WILL BE HELD ON 18 JUNE 2024 AT 9:00 A.M. ON 12TH FLOOR OF GLOBAL BUILDING, 19 DES VOE ROAD CENTRAL, HONG KONG. The meeting will include the approval of the Audited Consolidated Financial Statements for the year ended December 31, 2023, the Board's Report and the Auditor's Report, and the re-election of Ms. Wang Qiu Qin, Mr. Sui Ping and Mr. Leung Chi Kin as directors. IN ADDITION, THE GENERAL MEETING WILL DISCUSS THE RENEWAL OF MAASHIWAN ACCOUNTING FIRM AS AUDITOR AND AUTHORIZING THE BOARD OF DIRECTORS TO DETERMINE REMUNERATION, GRANT GENERAL MANDATES TO DISTRIBUTE, ISSUE OR DISPOSE OF COMPANY SHARES, AND AUTHORIZATION TO REPURCHASE COMPANY SHARES. Shareholders will appoint representatives to attend and vote at the General Meeting by proxy form.

NEW SHARP PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (“NEW SHARP PHARMACEUTICALS”) WILL BE HELD ON 18 JUNE 2024 AT 9:00 A.M. ON 12TH FLOOR OF GLOBAL BUILDING, 19 DES VOE ROAD CENTRAL, HONG KONG. The meeting will include the approval of the Audited Consolidated Financial Statements for the year ended December 31, 2023, the Board's Report and the Auditor's Report, and the re-election of Ms. Wang Qiu Qin, Mr. Sui Ping and Mr. Leung Chi Kin as directors. IN ADDITION, THE GENERAL MEETING WILL DISCUSS THE RENEWAL OF MAASHIWAN ACCOUNTING FIRM AS AUDITOR AND AUTHORIZING THE BOARD OF DIRECTORS TO DETERMINE REMUNERATION, GRANT GENERAL MANDATES TO DISTRIBUTE, ISSUE OR DISPOSE OF COMPANY SHARES, AND AUTHORIZATION TO REPURCHASE COMPANY SHARES. Shareholders will appoint representatives to attend and vote at the General Meeting by proxy form.